The American Dietetic Association commends Congress for passing a three-year reauthorization of the Ryan White CARE Act, the largest federal program specifically for people with HIV and AIDS, with new attention to the unique dietary needs of patients.
Pharmion Corporation (Nasdaq: PHRM) today announced new data presented from two studies of thalidomide in combination therapy, including updated results from the pivotal MM-003 study in first-line multiple myeloma, and results from a study examining the effect of the addition of thalidomide to a post-transplant regimen. The results of these studies were presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando, December 9-12, 2006).
Eli Lilly and Company (NYSE: LLY) announced today that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration’s Division of Drug Oncology Products (DDOP) for EVISTA? (raloxifene HCl) for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and postmenopausal women at high risk for breast cancer.
Roche announced today that a large, international Phase III study (NO16967) of 627 previously treated patients with advanced colorectal cancer met its primary endpoint of progression-free survival.
New clinical data presented today demonstrated that Tasigna? (nilotinib) eliminated or significantly reduced the presence of blood cells containing a defective chromosome in approximately half of adult patients with a form of life-threatening leukemia who developed resistance or intolerance to treatment with Glivec? (imatinib).
Genzyme Corporation (Nasdaq: GENZ) and Berlex Inc., a U.S. affiliate of Schering AG, Germany (FSE: SCH), majority-owned by the Bayer Group, today announced results from CAM307, an international Phase III clinical trial comparing Campath(R) (alemtuzumab) with chlorambucil in previously untreated patients with B-cell chronic lymphocytic leukemia (B-CLL).
Researchers at the University of Leicester have identified for the first time a gene which causes a distressing eye condition. Their discovery, as reported in the journal Nature Genetics, is expected to lead to better treatments for the condition.
SEER-Medicare analysis finds older men with early prostate cancer who were treated lived longer than those who were not treated. Study published in Dec. 13th issue of JAMA.
Researchers from the University of Wisconsin have identified a novel antiviral peptide that may inhibit influenza viruses including the H5N1 strain. They report their findings in the December 2006 issue of the Journal of Virology.
Recent findings of an observational study by researchers at the University of Pennsylvania School of Medicine suggest that men between 65-80 years of age who received treatment for early stage, localized prostate cancer lived significantly longer than men who did not receive treatment. The study will be published in the Dec. 13 issue of JAMA.